SEC Form 4 · accession 0001140361-26-027008
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gordon Carmichael
Director
Period of report
Jun 10, 2026
Accepted (ET)
Jun 30, 2026 · 6:17 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001124105
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $5.95 | Jun 10, 2026 | A | 40,000 | A | — | Jun 10, 2036 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date.